Fig. 1
From: LINC01224 promotes colorectal cancer progression through targeting miR-485-5p/MYO6 axis
The expression of LINC01224 and the interaction between LINC01224 and YY1 in CRC. A LINC01224 level in colon adenocarcinoma (COAD) and rectum adenocarcinoma (READ) was predicted via GEPIA with normalization to TCGA normal and GTEx data. Log2FC>1; P-value > 0.01. B LINC01224 abundance was determined via qPCR in CRC and normal control (NC) samples (n = 52). C The overall survival of patients was evaluated in LINC01224high and LINC01224low groups. D LINC01224 expression was detected via qPCR in CRC and control cell lines. E YY1 abundance was measured via qPCR in CRC tissues and NC samples (n = 52). F The linear correlation between YY1 and LINC01224 levels in CRC tissues. G YY1 expression was tested via western blotting in LoVo and SW620 cells with transfection of si-NC, si-YY1, vector, or YY1 overexpression vector. H LINC01224 expression was determined via qPCR in cells transfected with si-NC, si-YY1, vector, or YY1 overexpression vector. I The construction of pGL3-LINC01224-WT1, pGL3-LINC01224-MUT1, pGL3-LINC01224-WT2, and pGL3-LINC01224-MUT2. J Luciferase activity of pGL3-WT1, pGL3-MUT1, pGL3-WT2, and pGL3-MUT2 was determined in LoVo and SW620 cells co-transfected with YY1 overexpression vector or its control vector. K The affinity of YY1 to LINC01224 promoter was analyzed via ChIP assay. *P < 0.05